STOCK TITAN
  1. Home
  2. News
  3. SKYE

Skye Bioscience, Inc. - $SKYE STOCK NEWS

Welcome to our dedicated page for Skye Bioscience news (Ticker: $SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Skye Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Skye Bioscience's position in the market.

News

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) receives FDA clearance to initiate Phase 2 clinical trial of nimacimab, a peripherally-acting CB1 inhibitor, targeting obesity and chronic kidney disease. Nimacimab shows promising safety and tolerability in Phase 1b study, with encouraging trends in exploratory biomarkers. The molecule offers potential as a single or combination therapy for metabolic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
clinical trial
-
News

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) plans to develop nimacimab, a monoclonal antibody targeting the endocannabinoid system, for weight loss and obesity treatment. The Company filed an IND application with the FDA for a Phase 2 study in patients with obesity and chronic kidney disease. Nimacimab's safety profile is encouraging, showing potential for monthly dosing and convenient patient self-administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
clinical trial
-
News

Skye Bioscience Responds to OTC Markets Promotional Policy

Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYE) Receives Request from OTC Markets Group Inc. for Statement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYE) and Tautomer Bioscience (Pty) Limited have announced an agreement granting Tautomer an exclusive license to develop and commercialize Skye's proprietary THC prodrug, SBI-100, as a novel suppository application for chronic intractable pain and other indications in South Africa and the rest of Africa. The agreement includes development milestones, sales milestones, and tiered double-digit royalties on net product sales. Tautomer will also purchase Skye shares in open market transactions. This partnership aims to address the unmet medical need for non-opioid alternatives for chronic pain in South Africa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.55%
Tags
none
-
News

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion’s ability to lower intraocular pressure, safety, and relevant biomarkers in patients with primary open-angle glaucoma or ocular hypertension. The Phase 2 study will compare two concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days, with analysis of IOP data from 50% of patients enrolled to be performed in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) to present its glaucoma program at two ophthalmology-focused conferences, showcasing SBI-100 Ophthalmic Emulsion, a first-in-class CB1 agonist. The company will introduce recent Phase 1 data and discuss details of its Phase 2a clinical study. Executives will be available for 1x1 meetings at the BTIG 3rd Annual Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
conferences
News

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

Rhea-AI Summary
Skye Bioscience reports successful results from Phase 1 trial of SBI-100 OE, an ophthalmic drug targeting glaucoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.24%
Tags
clinical trial
-
News

Skye Bioscience Reverse Stock Split to Be Effective on September 8th

Rhea-AI Summary
Skye Bioscience, Inc. announces 1-for-250 reverse stock split effective September 8th. Total issued and outstanding shares will be approximately 12,312,551. No fractional shares will be issued. Stockholders' ownership interest and voting power remain virtually unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27243.8%
Tags
none
-
News

Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Skye Bioscience to present company overview at H.C. Wainwright 25th 3rd Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody

Rhea-AI Summary
Skye Bioscience expands resources and technologies with acquisition of Bird Rock Bio, raising $17M in new capital. Plans to advance Phase 2a glaucoma clinical trial with nimacimab and expects Phase 1 results for SBI-100 Ophthalmic Emulsion by end of Q3 2023. Skye's cash and cash equivalents expected to fund operations into 2024. Goal to uplist to a national stock exchange with proposed reverse stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
acquisition clinical trial
Stock SKYE logo
Skye Bioscience, Inc.

OTC:SKYE

SKYE Rankings

#3332 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SKYE Stock Data

335.69M
11.67M
7.09%
57.67%
General Freight Trucking, Long-Distance, Truckload
Transportation and Warehousing
Link
United States of America
SAN DIEGO

About SKYE

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.